Soga, N., Kageyama, T., Ogura, Y., Yamada, T., & Hayashi, N. (2016). Clinical Effect of Switching from a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients with Castration-Resistant Prostate Cancer and Serum Testosterone Level ≥ 20 ng/dl. Curr Urol.
Citação norma ChicagoSoga, Norihito, Takumi Kageyama, Yuji Ogura, Tomomi Yamada, and Norio Hayashi. "Clinical Effect of Switching From a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients With Castration-Resistant Prostate Cancer and Serum Testosterone Level ≥ 20 Ng/dl." Curr Urol 2016.
Citação norma MLASoga, Norihito, et al. "Clinical Effect of Switching From a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients With Castration-Resistant Prostate Cancer and Serum Testosterone Level ≥ 20 Ng/dl." Curr Urol 2016.